Deferasirox API, developed as a Level 2 knowledge-based product by Soroush Mana Pharmed, is utilized as the key active component in the manufacture of oral deferasirox medication. Approved by the U.S. Food and Drug Administration (FDA) in 2005, deferasirox is an iron chelating agent that promotes the excretion of excess iron from the body. It is primarily prescribed in cases of chronic iron overload resulting from long-term blood transfusions or conditions such as thalassemia, where iron toxicity becomes a concern.
Two molecules of deferasirox have the capacity to bind to a single iron atom, thereby reducing serum iron concentration. Iron excretion through this medication occurs mainly via the feces, with minimal renal elimination through the urine.